A study in JAMA Oncology reveals that MyProstateScore 2.0, a new urine test analyzing 18 genes, surpasses PSA in detecting significant prostate cancers and could reduce unnecessary biopsies by up to 42%.
A new urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to a study published on April 18 in JAMA Oncology. The urine test, MyProstateScore 2.0 (MPS2), was shown to meaningfully reduce unnecessary prostate biopsies while providing highly accurate detection of worrisome prostate cancers, the researchers concluded.
"In nearly 800 patients with an elevated PSA level, the new test was capable of ruling out the presence of clinically significant prostate cancer with remarkable accuracy. This allows patients to avoid more burdensome and invasive tests, like MRI and prostate biopsy, with great confidence that we are not missing something," said Jeffrey Tosoian, MD, assistant professor of Urology and director of Translational Cancer Research at Vanderbilt University Medical Center, who is first author of the study.
Jeffrey Tosoian, MD, assistant professor of Urology and director of Translational Cancer Research at Vanderbilt University Medical Center, who is first author of the study.
Credit: Vanderbilt University Medical Center
Background on Prostate Cancer Screening
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the U.S. The PSA blood test has been widely used as the initial step in prostate cancer screening. Although PSA is elevated in the vast majority of men with prostate cancer, it is also elevated in a significant proportion of men without cancer.
As a result, the use of elevated PSA alone to prompt a prostate biopsy results in numerous unnecessary biopsies. Although generally safe, prostate biopsies are invasive, uncomfortable, and carry some risk of worrisome complications. Therefore, for patients with an elevated PSA, there is a great need for a second-line test to better identify which men truly need a biopsy and which do not.
Development of MPS2
Because some low-grade, prostate cancers do not require treatment and can be safely monitored with an approach termed active surveillance, the MPS2 test was developed to detect more specifically the higher-grade, "clinically significant" cancers in need of early detection and treatment.
To do this, the research team analyzed prostate tumors from across the U.S. to identify novel genes more often detected in the presence of significant cancers. The most informative 18 genes were combined into the MPS2 test, which was then tested in a National Cancer Institute trial of men with an elevated PSA level.
Uniquely, the authors were able to compare the novel test to other prostate cancer tests, including the original, two-gene MPS test.
Study Results and Comparison
The study involved 743 men with a median age of 62 years and a median PSA level of 5.6. While existing biomarker tests could have avoided 15% to 30% of unnecessary biopsies (i.e. biopsies that were negative or found low-grade cancers not requiring treatment), use of MPS2 would have avoided 35% to 42% of unnecessary biopsies without missing any additional diagnoses of clinically significant cancer.
The improvement was even more pronounced in men with a history of a previous negative biopsy, reducing the rate of unnecessary biopsies from 46% to 51% with use of MPS2, as compared to 9% to 21% for existing tests.
Future Research and Limitations
Multiparametric magnetic resonance imaging (mpMRI) is another second-line test that has been utilized, but while it can improve detection of clinically significant prostate cancer, interpretation of the results can be subjective and vary significantly. The authors also noted that mpMRI is not available in some community settings and is not an option for some patients. The current study was not designed to compare biomarkers to mpMRI, but the researchers are currently conducting a prospective, multicenter trial for that purpose.
In patients shown to be without clinically significant prostate cancer by the new test, the authors concluded that the "externally validated performance of MPS2 supports its effectiveness in accurately ruling out the need for mpMRI and biopsy altogether." They noted a limitation of the study was that only 13% of participants were African American. Because prostate cancer is more prevalent among African American men, the research team is currently pursuing further analyses in more racially diverse populations.
For more on this research, see New Urine-Based Test Detects High-Grade Prostate Cancer.
Reference: "Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer" by Jeffrey J. Tosoian, Yuping Zhang, Lanbo Xiao, Cassie Xie, Nathan L. Samora, Yashar S. Niknafs, Zoey Chopra, Javed Siddiqui, Heng Zheng, Grace Herron, Neil Vaishampayan, Hunter S. Robinson, Kumaran Arivoli, Bruce J. Trock, Ashley E. Ross, Todd M. Morgan, Ganesh S. Palapattu, Simpa S. Salami, Lakshmi P. Kunju, Scott A. Tomlins, Lori J. Sokoll, Daniel W. Chan, Sudhir Srivastava, Ziding Feng, Martin G. Sanda, Yingye Zheng, John T. Wei, Arul M. Chinnaiyan, EDRN-PCA3 Study Group, Ian M. Thompson, Mohamed Bidair, Adam Kibel, Daniel W. Lin, Yair Lotan, Alan Partin, Samir Taneja, David H. Howard, Meredith M. Regan, Jack Groskopf, Jonathan Chipman, Dattatraya H. Patil, Douglas S. Scherr, Jacob Kagan, Jing Fan, Aron Y. Joon, Leonidas E. Bantis and Mark A. Rubin, 18 April 2024, JAMA Oncology.
DOI: 10.1001/jamaoncol.2024.0455
Tosoian is co-first author with Yuping Zhang, PhD, and Lanbo Xiao, PhD, professors at the University of Michigan, where Tosoian and Arul Chinnaiyan, MD, PhD, initiated the study. Chinnaiyan and John T. Wei, MD, are the study's senior authors. Other Vanderbilt researchers who contributed to the study are Nathan Samora, MD, and Hunter Robinson, MD.
The study received funding support from the Prostate Cancer Foundation Young Investigator Award (Tosoian), Michigan-Vanderbilt EDRN Biomarker Characterization Center (U2C CA271854), and the EDRN DMCC (U24 CA086368).
News
After only a short training, people in a coma managed to send targeted signals
Researchers have succeeded in communicating with brain-injured patients who are unconscious. They see enormous potential in this for future treatments. Patients who lie motionless in bed after a severe brain injury and do not [...]
MIT Scientists Reprogram Immune Cells Inside the Body To Destroy Cancer
Natural killer cells reprogrammed inside mice eliminated lymphoma tumors and helped damaged livers heal, though whether this approach could help people with cancer or autoimmune disease remains unknown. To make a cancer treatment from [...]
Melanoma mRNA Vaccine Shows Promise in Preventing Disease Recurrence
Key takeaways: Phase 3 trial finds personalized intismeran plus pembrolizumab may better prevent high-risk melanoma recurrence after surgery The trial enrolled 1,137 patients and builds on phase 2 results showing about half the recurrence [...]
Scientists Discover a Powerful New Weapon Against a Dangerous Gut Infection
The promise of an experimental treatment for C. difficile gut infections lies partly in the bacteria it leaves alive, according to early laboratory and mouse research. Broad-spectrum antibiotics can disrupt the gut’s microbial community, [...]
Your Bones May Hold a Hidden Clue to Blood Cancer Survival
For people with blood cancers called myelodysplastic syndromes, osteoporosis may hold an overlooked clue to survival, a three-year observational study suggests. In blood cancers that develop in the bone marrow, an important clue to [...]
Researchers Discover What Reading for Pleasure May Be Doing to Your Brain
Reading for pleasure may offer surprising benefits for the brain, with research linking the habit to better mental health, stronger cognitive abilities, and a lower risk of dementia. Reading for pleasure may do far [...]
Scientists Discover a Hidden Trigger That Keeps Inflammation Alive
Inflammation persists after proteins detach from immune receptors, revealing a potential target for autoimmune treatments. Since a Nobel Prize-winning discovery in the 1990s identified molecules called Toll-like Receptors as the guardians of the human [...]
A Virus Gives Itself Away the Moment It Attacks
Researchers have found the trigger behind a powerful bacterial defense against viruses. Viruses that prey on bacteria could become an increasingly important tool for treating bacterial infections, particularly as antibiotic resistance makes some infections [...]
Scientists Discover Aspirin May Slash Dementia Risk by 70% – but Only for Certain People
Aspirin was linked to a sharply lower dementia risk in some older adults, and their genes may hold the clue. A Monash University analysis found that older adults with a particular genetic profile had [...]
Inflammation May Awaken Dormant Cancer Cells Years After Treatment
The body’s response to inflammation may disturb cancer cells that have been lying silent for years, giving them an opportunity to grow again. Researchers at the Francis Crick Institute have found that gut inflammation [...]
Where do nanoparticles go once they enter the body?
New international best practice guidance, co-written at ANSTO, sets out how to measure where nanoparticles like titanium dioxide end up in the body and how long they remain. The guidance has been shared by [...]
Long-Acting HIV Shots Could Solve a Major Treatment Challenge for Young People
A major African trial suggests that changing how HIV treatment is delivered could significantly improve viral suppression in adolescents. Young people with HIV were more likely to keep the virus suppressed when they received [...]
WHO Factsheets – The top 10 causes of death
In 2023, the 10 leading causes of death accounted for 33 million deaths, or 54% of the total 61 million deaths worldwide. The top global causes of death, in order of total number of lives lost, [...]
Aging Cells May Be Hiding From the Immune System – Scientists Think They Know How
Your immune system is supposed to clear out damaged cells. Researchers may have found how some of them hide and linger as the body ages. Researchers led by Cedars-Sinai Health Sciences University have identified [...]
Your Voice May Reveal How Fast Your Brain Is Aging
Researchers have developed a machine-learning “speech clock” that estimates age from subtle patterns in how people speak and what they say. It is possible that people’s voices may contain certain signals of aging that [...]
Optogenetics Pioneers Win 2026 Nobel Prize in Physiology or Medicine
The 2026 Nobel Prize in Physiology or Medicine has been awarded to Peter Hegemann, Georg Nagel, and Karl Deisseroth for the development of optogenetics, a revolutionary technology that uses light to control individual neurons [...]
